Dopamine agonists and pathologic behaviors.

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Ropinirole and pramipexole are dopamine agonists with high affinity for the cerebral dopamine D3 receptor.
• These drugs are prescribed for Parkinson's disease.
• Adverse behavioral effects, including impulse control disorders, have been reported with their use.

Purpose of the Study:

• To investigate the causal relationship between dopamine D3 receptor affinity of ropinirole and pramipexole and the emergence of pathologic behavioral patterns.
• To explore the role of the dopamine D3 receptor in the limbic system concerning novelty, reward, and risk assessment.
• To identify the dopamine D3 receptor as a potential therapeutic target for psychiatric disorders.

Main Methods:

• Review of neuroanatomical, physiological, and behavioral science data.
• Analysis of clinical observations linking medication use to behavioral changes.
• Correlation of drug-receptor affinity with observed behavioral outcomes.

Main Results:

• Dopamine agonists ropinirole and pramipexole exhibit specific affinity for the dopamine D3 receptor.
• Patients treated with these drugs developed impulse control disorders (hypersexuality, gambling, etc.) without prior history.
• Behavioral changes remitted upon medication discontinuation, indicating a causal link.

Conclusions:

• The high D3 receptor affinity of ropinirole and pramipexole is the likely cause of emergent behavioral changes.
• The dopamine D3 receptor's role in the limbic system (novelty, reward, risk) is implicated.
• The D3 receptor is a potential therapeutic target for obsessive-compulsive disorder and substance abuse; understanding its function may inform future antipsychotic drug design.